Avirmax’s contract manufacturing services are dedicated to innovate and develop novel technologies with its clients to address current challenges in viral vector production based on its state-of-the-art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Our platform, staff and facilities integrate:

• Scalability & Productivity
• Speed & Flexibility
• Safety & Simplicity

The Avirmax team’s extensive experience with this unique vector system and many years in rAAV-based gene therapy process development, regulatory submission and approval at early and late phases will provide our clients with a best-in-class CDMO experience.